Sandostatin LAR | Market Exclusivity | US | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
NEW Find Prospects
- Prospector
Drugs in Dev.
News
Blog
Market Place
Login

Sandostatin LAR
US Exclusivities

PharmaCompass Sponsored Ads

Contact Supplier

Veranova: A CDMO that manages complexity with confidence.

Contact Supplier

pharmacompass-1-m-2026-04-20

PharmaCompass Sponsored Ads

Contact Supplier

Aspen API. More than just an API™

Contact Supplier

pharmacompass-2-m-2026-04-20

Sandostatin LAR

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

61 API Suppliers, 26 USDMF, 9 CEP/COS, 4 JDMF, 8 EU WC, 1 KDMF, 20 NDC API, 33 Listed Suppliers

61 API Suppliers
26 USDMF
9 CEP/COS
4 JDMF
8 EU WC
1 KDMF
20 NDC API
33 Listed Suppliers

DEVELOPMENTS

48 Drugs in Development

48 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

379 FDF Dossiers, 64 FDA Orange Book, 222 Europe, 14 Canada, 48 Australia, 8 South Africa, 23 Listed Dossiers

379 FDF Dossiers
64 FDA Orange Book
222 Europe
14 Canada
48 Australia
8 South Africa
23 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 0.05MG BASE/ML, INJECTABLE;INJECTION - EQ 0.1MG BASE/ML, INJECTABLE;INJECTION - EQ 0.2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 0.5MG BASE/ML, INJECTABLE;INJECTION - EQ 1MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;SUBCUTANEOUS - EQ 7MG BASE/2.8ML (EQ 2.5MG BASE/ML)

INJECTABLE;INJECTION - EQ 0.05MG BASE/ML
INJECTABLE;INJECTION - EQ 0.1MG BASE/ML
INJECTABLE;INJECTION - EQ 0.2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
INJECTABLE;INJECTION - EQ 0.5MG BASE/ML
INJECTABLE;INJECTION - EQ 1MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
SOLUTION;SUBCUTANEOUS - EQ 7MG BASE/2.8ML (EQ 2.5MG BASE/ML)

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 14 SPI Pharma, 1 Gangwal Healthcare, 1 Pfanstiehl, 3 Kirsch Pharma, 3 Dr. Paul Lohmann GmbH & Co. KGaA, 2 Actylis, 1 BASF, 1 Finar, 2 Gangwal Chemicals, 1 Ingredion Pharma Solutions, 1 Kerry, 2 Microlex e.U, 1 Pluviaendo, 3 Roquette, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Sigachi Industries

1 Rochem International Inc
14 SPI Pharma
1 Gangwal Healthcare
1 Pfanstiehl
3 Kirsch Pharma
3 Dr. Paul Lohmann GmbH & Co. KGaA
2 Actylis
1 BASF
1 Finar
2 Gangwal Chemicals
1 Ingredion Pharma Solutions
1 Kerry
2 Microlex e.U
1 Pluviaendo
3 Roquette
1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd
1 Shijiazhuang Huaxu Pharmaceutical
1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

17 Fillers, Diluents & Binders, 12 Chewable & Orodispersible Aids, 10 Direct Compression, 10 Taste Masking, 10 Parenteral, 7 Disintegrants & Superdisintegrants, 4 API Stability Enhancers, 3 Granulation, 3 Co-Processed Excipients, 1 Topical, 1 Thickeners and Stabilizers, 1 Solubilizers

17 Fillers, Diluents & Binders
12 Chewable & Orodispersible Aids
10 Direct Compression
10 Taste Masking
10 Parenteral
7 Disintegrants & Superdisintegrants
4 API Stability Enhancers
3 Granulation
3 Co-Processed Excipients
1 Topical
1 Thickeners and Stabilizers
1 Solubilizers

DIGITAL CONTENT

2 Data Compilation #PharmaFlow, 44 News #PharmaBuzz

2 Data Compilation #PharmaFlow
44 News #PharmaBuzz

GLOBAL SALES INFORMATION

12 US Medicaid Prescriptions, 47 Regulatory FDF Prices, 11 Annual Reports

12 US Medicaid Prescriptions
47 Regulatory FDF Prices
11 Annual Reports

MARKET PLACE

20 APIs, 16 FDF Dossiers

20 APIs
16 FDF Dossiers

PATENTS & EXCLUSIVITIES

29 US Patents, 4 US Exclusivities, 7 Health Canada Patents

29 US Patents
4 US Exclusivities
7 Health Canada Patents

REF. STANDARDS & IMPURITIES

6 Others

6 Others

Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Name Reset all filters

4 All

01 1CHIESI

02 3MYLAN LABS LTD

filter Product Reset all filters

4 All

01 4OCTREOTIDE ACETATE

filter Exclusivity Expiration Date Reset all filters

4 All

01 22026-07-27

02 12026-08-02

03 12027-06-26

filter Exclusivity Code Reset all filters

4 All

01 3CGT

02 1ODE-474

Bachem Octreotide Acetate

Product Main Page

MYLAN LABS LTD

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

OCTREOTIDE ACETATE

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

CGT

Exclusivity Expiration Date

2026-07-27

Application Number

216589

Product Number

3

Exclusivity Details

01

MYLAN LABS LTD

OCTREOTIDE ACETATE

AACR Annual meeting

Not Confirmed

MYLAN LABS LTD

U.S.A

AACR Annual meeting

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

OCTREOTIDE ACETATE

Exclusivity Code : CGT

Exclusivity Expiration Date : 2026-07-27

Application Number : 216589

Product Number : 3

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

MYLAN LABS LTD

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

OCTREOTIDE ACETATE

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

CGT

Exclusivity Expiration Date

2026-07-27

Application Number

216589

Product Number

2

Exclusivity Details

02

MYLAN LABS LTD

OCTREOTIDE ACETATE

AACR Annual meeting

Not Confirmed

MYLAN LABS LTD

U.S.A

AACR Annual meeting

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

OCTREOTIDE ACETATE

Exclusivity Code : CGT

Exclusivity Expiration Date : 2026-07-27

Application Number : 216589

Product Number : 2

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

MYLAN LABS LTD

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

OCTREOTIDE ACETATE

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

CGT

Exclusivity Expiration Date

2026-08-02

Application Number

216589

Product Number

1

Exclusivity Details

03

MYLAN LABS LTD

OCTREOTIDE ACETATE

AACR Annual meeting

Not Confirmed

MYLAN LABS LTD

U.S.A

AACR Annual meeting

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

OCTREOTIDE ACETATE

Exclusivity Code : CGT

Exclusivity Expiration Date : 2026-08-02

Application Number : 216589

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

CHIESI

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

OCTREOTIDE ACETATE

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

ODE-474

Exclusivity Expiration Date

2027-06-26

Application Number

208232

Product Number

1

Exclusivity Details

04

CHIESI

OCTREOTIDE ACETATE

AACR Annual meeting

Not Confirmed

CHIESI

U.S.A

AACR Annual meeting

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

OCTREOTIDE ACETATE

Exclusivity Code : ODE-474

Exclusivity Expiration Date : 2027-06-26

Application Number : 208232

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.